RSV research Group - Group Bont-Meyaard

RSV research Group - Group Bont-Meyaard

Kind aan de beademing

About uitklapper, klik om te openen

The RSV Research Group has the vision to combine clinical and basic research to decrease the global burden of RSV infection. Our mission is to improve knowledge of RSV epidemiology, and to develop safe and effective therapeutic and preventive interventions. The RSV Research Group consists of clinician scientists and lab researchers focusing on the epidemiology and pathogenesis of RSV bronchiolitis. RSV infections cause a major burden for patients, their parents and society. RSV infection is the second most frequent cause of death during infancy, only malaria is associated with higher mortality.

Group members uitklapper, klik om te openen

Groep Bont

Group Leaders

prof. dr. L.J. Bont

prof. dr. L.J. Bont Full Professor

Dr. Bont has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU has received major funding (>€100,000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, Janssen, Pfizer, the Bill and Melinda Gates Foundation and MeMed Diagnostics. UMCU has received major cash or in kind funding as part of the public private partnership IMI-funded RESCEU project from GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in the INFORM study sponsored by MedImmune. UMCU has received minor funding for participation in trials by Regeneron and Janssen from 2015-2017 (total annual estimate less than €20,000). UMCU received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, GSK, Bavaria Nordic, MabXience, Novavax, Pfizer, Janssen (total annual estimate less than €20,000). Dr. Bont is the founding chairman of the ReSViNET Foundation.

prof. dr. L. Meyaard

prof. dr. L. Meyaard Full Professor

Senior researchers

  • Joanne Wildenbeest
  • Katrien Oude Rengerink


  • Margreet Westerlaken

PhD students

  • Koos Korsten
  • Natalie Mazur
  • Sjanna Besteman
  • Arthur van Stigt
  • Annefleur Langedijk
  • Yvette Lowensteyn
  • Roy Zuurbier
  • Marie Billard

Patient advisory board

  • Nicole Derksen-Lazet, lead Patient Advisory Board
  • Inge Oliemans, communication Patient Advisory Board

Research nurses

  • Loes Nibbelke
  • Brigitte Buiteman

ReSViNET Foundation

Leyla Kragten-Tabatabaie, Board of Directors ReSViNET Foundation

Key publications uitklapper, klik om te openen

  1. Blanken, M. O., et al. (2013). "Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants." 368(19): 1791-1799.Blanken, M. O., et al. (2013). View
  2. Mazur, N. I., et al. (2015). "Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics." Lancet Respir Med 3(11): 888-900. View
  3. van Houten, C. B., et al. (2017). "A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study." Lancet Infect Dis 17(4): 431-440. View
  4. Scheltema, N. M., et al. (2018). "Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial." Lancet Respir Med 6(4): 257-264. View
  5. Mazur, N. I., et al. (2018). "The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates." Lancet Infect Dis 18(10): e295-e311. View

RSV infection and wheeze in moderate-to-late preterm infants prediction and cost-effectiveness

Marteen Blanken


Improving diagnosis of bacterial infections

Chantal van Houten


Respiratory syncytial virus-related disease burden in young children

 Nienke Scheltema

Innate immunity in RSV infection

Tina Faber


> see all PhD theses 

Grants uitklapper, klik om te openen

2017 - Respiratory Syncitial virus Consortium in Europe(RESCUE, IMI)

2016 - RSV GOLD (BMGF)

2014 - Longfonds Consortium Grant

Support our research uitklapper, klik om te openen

  • Resvinet foundation

Collaborations uitklapper, klik om te openen


funded by Bill and Melinda Gates Foundation


for biomarker research to diagnose bacterial infection

ReSViNET Network

for RSV Research, chairman


for biomarker discovery of virus versus bacterial respiratory tract infection

RESCEU Network

for RSV Burden of Disease studies (funded by IMI/H2020)

RSV Society

under ISIRV

Education & Courses uitklapper, klik om te openen

  • International conference: RSVVW, Accra, Ghana
  • Summer school on Global Child Health, Utrecht

Research programs uitklapper, klik om te openen

  • Infection and Immunity
  • Child Health

Research interests/topics uitklapper, klik om te openen

Epidemiology and pathogenesis of RSV bronchiolitis

Contact uitklapper, klik om te openen

Related website

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not